Sorafenib Stimulates Human Skin Type Mast Cell Degranulation and Maturation

August 2017 in “ Journal of dermatological science ”

Yukari Mizukami, Koji Sugawara, Yukimi Kira, Daisuke Tsuruta

sorafenib mast cells degranulation PI3K signaling stem cell factor SCF skin reactions

Studysummary This study found that sorafenib increased mast cell number and degranulation in skin, suggesting PI3K signaling and SCF production may underlie its adverse cutaneous reactions.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study investigated the effects of sorafenib on skin-type mast cells (MCs) and found that it significantly increased the number and degranulation of MCs in human skin samples, without affecting their proliferation and apoptosis. This indicated that sorafenib stimulated MC maturation from resident precursors through PI3K signaling and increased stem cell factor (SCF) expression. The findings suggested that targeting PI3K signaling or SCF could be potential strategies for managing sorafenib-induced skin reactions.

View this study on jdsjournal.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Patient-Level Adverse Event Patterns in a Single-Institution Study of the Multi-Kinase Inhibitor Sorafenib

10 citations , July 2016 in “Clinical and translational science”

In this study, sorafenib's common adverse events, like a hand-foot syndrome and diarrhea, were observed in distinct temporal and tissue distribution patterns, revealing new relationships among effects.

research Endocannabinoids Limit Excessive Mast Cell Maturation And Activation In Human Skin

124 citations , January 2012 in “Journal of Allergy and Clinical Immunology”

This study found that activation of cannabinoid 1 receptors in human scalp hair follicles may limit excessive mast cell activation and maturation, suggesting a potential therapeutic strategy for managing MC-dependent skin diseases.

research Hand-Foot and Stump Syndrome Due to Sorafenib

45 citations , January 2007 in “Journal of Clinical Oncology”

This case report identifies hand-foot and stump syndrome as a potential side effect of sorafenib therapy in a 47-year-old man with a leg amputation.